You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Duac vs erythromycin/zinc (Zineryt)

Go to Close Top

  • DUAC 5%: FASTER ONSET OF ACTION VS ERYTHROMYCIN/ZINC 1

    • Duac 5% provides significantly greater reductions (median) in inflammatory lesions vs erythromycin/zinc at week 2 (p=0.029) 1
    • Significantly more patients had a ≥30% reduction in inflammatory and non-inflammatory lesions by week 2 with Duac 5% vs erythromycin/zinc (primary endpoint) 1

    Onset of action

    *p=0.029 Duac vs erythromycin/zinc
    † % shown on this graph were derived from the changes in absolute lesion count from week 0 to 2, therefore, p values are not available. The same results were first published in Langner, et al. 2007. The graph has been independently created by GSK from the original publication.

  • DUAC 5%: COMPARABLE TOLERABILITY TO ERYTHROMYCIN/ZINC 1

    • Patients using Duac 5% experienced a similar rate of treatment-related adverse events to patients using erythromycin/zinc 1
    • The most common adverse events in both groups were application site reactions, including dryness, desquamation, burning and erythema 1
    Duac tolerability

    *% shown on this graph were derived from the changes in absolute lesion count from week 0 to 2, therefore, p values are not available. The same results were first published in Langner, et al. 2007. The graph has been independently created by GSK from the original publication.

  • Duac is a fixed-dose combination that brings together the benefits of clindamycin and benzoyl peroxide, in an easy-to-use once-daily gel 2

    Easy-to-use once-daily
  • DUAC 5%: COMPARABLE REDUCTION IN LESIONS VS ERYTHROMYCIN/ZINC 1

    • Duac 5% provides comparable reductions in inflammatory and non-inflammatory lesions to erythromycin/zinc at week 12 1
    Duac 5% efficacy

    *% shown on this graph were derived from the changes in absolute lesion count from week 0 to 12, therefore, p values are not available. The same results were first published in Langner, et al. 2007. The graph has been independently created by GSK from the original publication

  • DUAC: DUAL-ACTION FORMULA WITH ADDED EMOLLIENTS FOR SKIN MOISTURISATION

    • Clindamycin and BPO work together to produce free radicals which oxidise bacterial proteins and enhance the antibacterial effect of clindamycin 34
    • Duac also contains dimethicone as well as glycerol,5 for added moisturization to mitigate potential irritant effects 6
    Duac formulation

    BPO: Benzoyl peroxide

  • DUAC: HELPS REDUCE THE RISK OF ANTIBIOTIC RESISTANCE 72

    In a pre-specified sub-group analysis study, Duac 5% was shown to: 7

    • Help prevent the development of antibacterial resistant Propionibacterium acnes
    • Reduce the number of strains of existing antibacterial resistant bacteria on the skin
    Anti-microbial resistance

    The same results were first published in Langner A, et al. 2008.
    The graph has been independently created by GSK from the original publication.

  • DUAC: HIGH STRENGTH RECOMMENDATION BY EDF GUIDELINES FOR MILD TO MODERATE ACNE TREATMENT 8

    EDF treatment guidelines recommend against the use of topical antibiotics as monotherapy due to the emergence of antibiotic-resistant strains of P. acnes 8

    Treatmenrt guidelines

    BPO: Benzoyl peroxide; EDF: European Dermatology Forum; FDC: Fixed-dose combination.

  • DUAC 3%: A LOW-CONCENTRATION BPO OPTION TO MEET DIFFERENT PATIENTS' NEEDS 9

    Duac 3% provides: 10

    • A faster onset of action vs clindamycin 1% (p<0.001)
    • Superior reductions in inflammatory lesions vs clindamycin 1% (p<0.001) and vs BPO 3% at week 12 (p=0.015)
    • Comparable tolerability with a similar rate of treatment-related adverse events to clindamycin 1% and BPO 3%

    *p<0.001 Duac vs clindamycin; † p=0.005 Duac vs BP02; ‡ p=0.199 (ns) Duac vs BPO.
    The same results were first published in Eichenfield, et al. 2011.
    The graph has been independently created by GSK from the original publication. BPO: Benzoyl peroxide.

Reference:

  1. Langner A, et al. JEADV2007;21(3):311-319.
  2. Duac 5% Summary of Product Characteristics (UK). January 2015.
  3. Burkhart CG, Burkhart CN. Br J Dermatol 2008;159(2):480-481.
  4. Dutil M. Skin Therapy Lett 2010;15(10):5-7.
  5. Dhawan SS. Cutis 2009;83(5):265-272.
  6. Draelos ZD. Plast Reconstr Surg 2010;125(2):719-724.
  7. Langner A, et al. Br J Dermatol 2008;158(1):122-129.
  8. European Dermatology Forum S3-Guideline for the Treatment of Acne (Update 2016). Available at: http://www.euroderm.org/edf/index.php/edf-guidelines/category/4-guidelines-acne?download=64:guideline-for-the-treatment-of-acne-update-2016 (Last accessed June 2018).
  9. Duac 3% Summary of Product Characteristics (UK). January 2015.
  10. Eichenfield LF, et al. J Drugs Dermatol 2011;10(12):1382-1396.

Duac is a registered trademark of the GlaxoSmithKline group of companies.